LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

Inicio・Lista de Acciones・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Cerrado

SectorSalud

3.72 -0.53

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.65

Máximo

3.79

Métricas clave
By Trading Economics
Ingresos	3.4M -9.8M
Empleados	34
EBITDA	-2.1M -13M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+444.96% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	71M 335M
Apertura anterior	4.25
Cierre anterior	3.72

Noticias sobre sentimiento de mercado

By Acuity

41%

59%

137 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

8.275 / 9.312 Soporte y Resistencia

Anavex Life Sciences Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

23 dic 2025, 15:21 UTC

Ganancias

Correction to Home Depot Outlook Headline on Dec. 9

23 dic 2025, 23:54 UTC

Charlas de Mercado

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23 dic 2025, 23:40 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

23 dic 2025, 21:21 UTC

Adquisiciones, fusiones, absorciones

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23 dic 2025, 21:20 UTC

Adquisiciones, fusiones, absorciones

St Barbara to Hold Deposit in Escrow

23 dic 2025, 21:20 UTC

Adquisiciones, fusiones, absorciones

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23 dic 2025, 21:19 UTC

Adquisiciones, fusiones, absorciones

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23 dic 2025, 21:13 UTC

Adquisiciones, fusiones, absorciones

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23 dic 2025, 20:16 UTC

Charlas de Mercado

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23 dic 2025, 20:14 UTC

Charlas de Mercado

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23 dic 2025, 19:13 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23 dic 2025, 18:58 UTC

Charlas de Mercado

Gold Has Another Record-Setting Day -- Market Talk

23 dic 2025, 18:32 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23 dic 2025, 17:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

23 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

23 dic 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

23 dic 2025, 17:09 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23 dic 2025, 16:21 UTC

Charlas de Mercado

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23 dic 2025, 16:16 UTC

Charlas de Mercado

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23 dic 2025, 16:15 UTC

Charlas de Mercado

Precious Metals Pare Gains -- Market Talk

23 dic 2025, 16:03 UTC

Adquisiciones, fusiones, absorciones

Erste Group Bank: Closing Expected Around Mid-January

23 dic 2025, 16:03 UTC

Adquisiciones, fusiones, absorciones

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23 dic 2025, 16:02 UTC

Adquisiciones, fusiones, absorciones

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23 dic 2025, 16:01 UTC

Adquisiciones, fusiones, absorciones

Erste Group Bank Receives Green Light for Acquisition in Poland

23 dic 2025, 15:42 UTC

Adquisiciones, fusiones, absorciones

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23 dic 2025, 15:42 UTC

Adquisiciones, fusiones, absorciones

Telefonica Doesn't Set Out Financial Details of Divestment

23 dic 2025, 15:41 UTC

Adquisiciones, fusiones, absorciones

Telefonica: Deal Will Allow Focus on Core Markets

23 dic 2025, 15:40 UTC

Adquisiciones, fusiones, absorciones

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23 dic 2025, 15:19 UTC

Charlas de Mercado

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp Esperado

Precio Objetivo

By TipRanks

444.96% repunte

Estimación a 12 meses

Media 20 USD 444.96%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

8.275 / 9.312Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

137 / 374 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.